{"success":true,"data":{"pressRelease":{"id":"168305","rtpr_id":"nACSq29tHa-20261013","ticker":"AIML","exchange":"","all_tickers":["AIML"],"title":"AI/ML Innovations Announces Completion of Share Issuance","author":"ACCESSWIRE","published_at":"2026-10-13T23:56:18.587Z","article_body":"TORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / October 13,\n2026 / AI/ML Innovations Inc. (\"AIML\" or the \"Company\")\n(CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence\nand neural-network-based technologies for digital health, announces that it\nhas completed its previously announced share for debt issuance with certain\nservice providers of the Company pursuant to which the Company has issued an\naggregate of 7,744,062 common shares (the \"Subject Shares\") at a deemed price\nof CAD$0.05 per Subject Share totaling CAD$387,203 in consideration of past\nservices and satisfaction of outstanding indebtedness (the \"Debt Settlement\").\n\nThe Subject Shares are subject to a statutory hold period expiring on February\n10, 2027.\n\nInsiders of the Company expect to purchase, directly or indirectly, an\naggregate of 4,900,001 Subject Shares, as a result of which the issuance is a\n\"related party transaction\" under Multilateral Instrument 61-101 - Protection\nof Minority Security Holders in Special Transactions (\"MI 61- 101\"). The\nCompany is exempt from the formal valuation and minority shareholder approval\nrequirements of MI 61-101 pursuant to the exemptions contained in Sections\n5.5(b) and 5.7(1)(a) of MI 61-101 on the basis that the Company is listed on\nthe Canadian Securities Exchange and neither the fair market value (as\ndetermined under MI 61-101) of the subject matter of, nor the fair market\nvalue of the consideration for, the Subject Shares, insofar as it involves the\nrelated parties, exceeded 25% of the Company's market capitalization (as\ndetermined under MI 61-101).\n\nThis news release does not constitute an offer to sell or a solicitation of an\noffer to buy nor shall there be any sale of any of the securities in any\njurisdiction in which such offer, solicitation or sale would be unlawful,\nincluding any of the securities in the United States of America. The\nsecurities described herein have not been and will not be registered under the\nUnited States Securities Act of 1933, as amended (the \"1933 Act\") or any state\nsecurities laws and may not be offered or sold within the United States or to,\nor for account or benefit of, U.S. Persons (as defined in Regulation S under\nthe 1933 Act) unless registered under the 1933 Act and applicable state\nsecurities laws, or an exemption from such registration requirements is\navailable.\n\nAbout AI/ML Innovations Inc.\n\nAIML Innovations Inc. is a global technology company pioneering the use of\nartificial intelligence and neural networks to transform digital health. Our\nproprietary platforms leverage advanced signal processing and deep learning to\nconvert complex biometric data into actionable insights - supporting earlier\ndiagnosis, personalized treatment, and more effective care.\n\nAIML's common shares trade on the Canadian Securities Exchange (CSE:AIML), the\nOTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).\n\nFor detailed information please see AIML's website at www.aiml-innovations.com\nor the Company's filed documents at www.sedarplus.ca.\n\nAIML Contact:\nPaul Duffy, Executive Chairman and CEO\nask@aiml-innovations.com\n416-941-8900\n\nNeither the CSE nor its Regulation Services Provider (as that term is defined\nin the policies of the CSE) accepts responsibility for the adequacy or\naccuracy of this release.\n\nForward Looking Statements - Certain information set forth in this news\nrelease may contain forward-looking statements that involve substantial known\nand unknown risks and uncertainties, including risks associated with the\nimplementation of the Company's products and services as currently proposed or\nat all. These forward-looking statements are subject to numerous risks and\nuncertainties, certain of which are beyond the control of the Company,\nincluding with respect to the nature and timing of future operations and the\nreceipt of all applicable regulatory approvals. Readers are cautioned that the\nassumptions used in the preparation of such information, although considered\nreasonable at the time of preparation, may prove to be imprecise and, as such,\nundue reliance should not be placed on forward-looking statements.\n\nSOURCE: AI/ML Innovations Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/publishing-and-media/ai%2fml-innovations-announces-completion-of-share-issuance-1236623)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSq29tHa-20261013","title":"AI/ML Innovations Announces Completion of Share Issuance","author":"ACCESSWIRE","ticker":"AIML","created":"2026-10-13T23:56:18.587Z","tickers":["AIML"],"exchange":"","article_body":"TORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / October 13,\n2026 / AI/ML Innovations Inc. (\"AIML\" or the \"Company\")\n(CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence\nand neural-network-based technologies for digital health, announces that it\nhas completed its previously announced share for debt issuance with certain\nservice providers of the Company pursuant to which the Company has issued an\naggregate of 7,744,062 common shares (the \"Subject Shares\") at a deemed price\nof CAD$0.05 per Subject Share totaling CAD$387,203 in consideration of past\nservices and satisfaction of outstanding indebtedness (the \"Debt Settlement\").\n\nThe Subject Shares are subject to a statutory hold period expiring on February\n10, 2027.\n\nInsiders of the Company expect to purchase, directly or indirectly, an\naggregate of 4,900,001 Subject Shares, as a result of which the issuance is a\n\"related party transaction\" under Multilateral Instrument 61-101 - Protection\nof Minority Security Holders in Special Transactions (\"MI 61- 101\"). The\nCompany is exempt from the formal valuation and minority shareholder approval\nrequirements of MI 61-101 pursuant to the exemptions contained in Sections\n5.5(b) and 5.7(1)(a) of MI 61-101 on the basis that the Company is listed on\nthe Canadian Securities Exchange and neither the fair market value (as\ndetermined under MI 61-101) of the subject matter of, nor the fair market\nvalue of the consideration for, the Subject Shares, insofar as it involves the\nrelated parties, exceeded 25% of the Company's market capitalization (as\ndetermined under MI 61-101).\n\nThis news release does not constitute an offer to sell or a solicitation of an\noffer to buy nor shall there be any sale of any of the securities in any\njurisdiction in which such offer, solicitation or sale would be unlawful,\nincluding any of the securities in the United States of America. The\nsecurities described herein have not been and will not be registered under the\nUnited States Securities Act of 1933, as amended (the \"1933 Act\") or any state\nsecurities laws and may not be offered or sold within the United States or to,\nor for account or benefit of, U.S. Persons (as defined in Regulation S under\nthe 1933 Act) unless registered under the 1933 Act and applicable state\nsecurities laws, or an exemption from such registration requirements is\navailable.\n\nAbout AI/ML Innovations Inc.\n\nAIML Innovations Inc. is a global technology company pioneering the use of\nartificial intelligence and neural networks to transform digital health. Our\nproprietary platforms leverage advanced signal processing and deep learning to\nconvert complex biometric data into actionable insights - supporting earlier\ndiagnosis, personalized treatment, and more effective care.\n\nAIML's common shares trade on the Canadian Securities Exchange (CSE:AIML), the\nOTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).\n\nFor detailed information please see AIML's website at www.aiml-innovations.com\nor the Company's filed documents at www.sedarplus.ca.\n\nAIML Contact:\nPaul Duffy, Executive Chairman and CEO\nask@aiml-innovations.com\n416-941-8900\n\nNeither the CSE nor its Regulation Services Provider (as that term is defined\nin the policies of the CSE) accepts responsibility for the adequacy or\naccuracy of this release.\n\nForward Looking Statements - Certain information set forth in this news\nrelease may contain forward-looking statements that involve substantial known\nand unknown risks and uncertainties, including risks associated with the\nimplementation of the Company's products and services as currently proposed or\nat all. These forward-looking statements are subject to numerous risks and\nuncertainties, certain of which are beyond the control of the Company,\nincluding with respect to the nature and timing of future operations and the\nreceipt of all applicable regulatory approvals. Readers are cautioned that the\nassumptions used in the preparation of such information, although considered\nreasonable at the time of preparation, may prove to be imprecise and, as such,\nundue reliance should not be placed on forward-looking statements.\n\nSOURCE: AI/ML Innovations Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/publishing-and-media/ai%2fml-innovations-announces-completion-of-share-issuance-1236623)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T23:56:18.633580978Z","server_sent_at_ms":1791935778633},"received_at":"2026-10-13T23:56:18.683Z","source_url":"https://www.accessnewswire.com/newsroom/en/publishing-and-media/ai%2fml-innovations-announces-completion-of-share-issuance-1236623"},"analysis":{"id":"156576","press_release_id":"168305","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":["debt settled via share issuance at CAD$0.05 -- signals cash constraints","related party transaction: insiders taking ~63% of the issued shares","micro-cap valuation exemption used to skip formal valuation/minority approval"],"eventType":"dilution","narrative":"AI/ML Innovations completed a share-for-debt issuance of 7,744,062 common shares at a deemed price of CAD$0.05 per share, settling CAD$387,203 owed to certain service providers.\n\nInsiders expect to take 4,900,001 of the shares, making this a related party transaction under Multilateral Instrument 61-101, from which the Company is exempt from formal valuation and minority approval requirements.\n\nThe shares are subject to a statutory hold period expiring February 10, 2027. The settlement adds dilution and paying obligations in stock rather than cash is a soft signal of constrained liquidity for this micro-cap digital health company.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Small share-for-debt settlement with heavy insider participation -- watch dilution trend in a cash-strapped micro-cap."},"keyFigures":{"offeringPrice":"CAD$0.05","sharesOffered":7744062,"customDimensions":{"debt_settled":"CAD$387,203","hold_period_expiry":"February 10, 2027","insider_share_purchase":4900001}},"namedEntities":{"people":[{"name":"Paul Duffy","role":"Executive Chairman and CEO"}],"products":[],"companies":[{"name":"AI/ML Innovations Inc.","ticker":"AIML"}],"dollarAmounts":[{"amount":"CAD$387,203","context":"total consideration for debt settlement via share issuance"},{"amount":"CAD$0.05","context":"deemed price per Subject Share"}]},"materialImpact":{"score":2,"reasoning":"Completion of a small share-for-debt settlement (~CAD$387K) that increases share count; small absolute size for this micro-cap limits impact, but paying service providers in stock signals cash constraints and the related-party component raises governance questions."},"tickerRelevance":{"others":[],"primary":"AIML"},"globalImportance":10,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"minor dilutive debt settlement","issuerAuthored":true,"relatedPartyAngle":true}},"event_type":"dilution","event_type_secondary":null,"sentiment":"bearish","material_impact_score":2,"narrative":"AI/ML Innovations completed a share-for-debt issuance of 7,744,062 common shares at a deemed price of CAD$0.05 per share, settling CAD$387,203 owed to certain service providers.\n\nInsiders expect to take 4,900,001 of the shares, making this a related party transaction under Multilateral Instrument 61-101, from which the Company is exempt from formal valuation and minority approval requirements.\n\nThe shares are subject to a statutory hold period expiring February 10, 2027. The settlement adds dilution and paying obligations in stock rather than cash is a soft signal of constrained liquidity for this micro-cap digital health company.","key_figures":{"offeringPrice":"CAD$0.05","sharesOffered":7744062,"customDimensions":{"debt_settled":"CAD$387,203","hold_period_expiry":"February 10, 2027","insider_share_purchase":4900001}},"named_entities":{"people":[{"name":"Paul Duffy","role":"Executive Chairman and CEO"}],"products":[],"companies":[{"name":"AI/ML Innovations Inc.","ticker":"AIML"}],"dollarAmounts":[{"amount":"CAD$387,203","context":"total consideration for debt settlement via share issuance"},{"amount":"CAD$0.05","context":"deemed price per Subject Share"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T23:56:24.011Z","global_importance":10,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"minor dilutive debt settlement","issuerAuthored":true,"relatedPartyAngle":true}},"durationMs":5316,"modelName":"glm-5.3-flashx"}}